Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.

Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V

Open source

DOI: 10.1016/j.ijgc.2025.101812
Published: 2025 Sep
Container: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2025.101812,
  title = {Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.},
  author = {Eskander RN and Lee JY and Mirza MR and Lorusso D and MacKay H and Ray-Coquard I and Oaknin A and Gonzalez-Martin A and Hasegawa K and Corr BR and Wu X and Leary A and Hu T and Dutta L and Okpara CE and McKenzie J and Makker V},
  year = {2025},
  journal = {International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  doi = {10.1016/j.ijgc.2025.101812},
  url = {https://doi.org/10.1016/j.ijgc.2025.101812}
}

RIS

TY  - JOUR
TI  - Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.
AU  - Eskander RN
AU  - Lee JY
AU  - Mirza MR
AU  - Lorusso D
AU  - MacKay H
AU  - Ray-Coquard I
AU  - Oaknin A
AU  - Gonzalez-Martin A
AU  - Hasegawa K
AU  - Corr BR
AU  - Wu X
AU  - Leary A
AU  - Hu T
AU  - Dutta L
AU  - Okpara CE
AU  - McKenzie J
AU  - Makker V
PY  - 2025
JO  - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
DO  - 10.1016/j.ijgc.2025.101812
UR  - https://doi.org/10.1016/j.ijgc.2025.101812
ER  -

APA

RN, E., JY, L., MR, M., D, L., H, M., I, R., A, O., A, G., K, H., BR, C., X, W., A, L., T, H., L, D., CE, O., J, M., & V, M. (2025). Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. https://doi.org/10.1016/j.ijgc.2025.101812

Source records

pubmed · retrieved 2026-09-26T20:21:14.206Z
europe-pmc · retrieved 2026-09-26T20:21:14.232Z
hal · retrieved 2026-09-26T20:21:14.249Z